EFV is manufactured by Merck and is used to treat HIV/AIDS. ## Compulsory licenses Compulsory licenses have been issued for EFV in the following instance: ### Brazil issued on May 01, 2007 [[Brazil]]'s provisions on compulsory licences can be in the Industrial Property Law (Law No. 9,279/1996). A compulsory licence may be granted under the following grounds: - Non-working or insufficient working If the patented invention is not being worked (i.e., not being utilised/manufactured) in Brazil or is not meeting domestic demand. - Refusal to grant licences on reasonable terms The applicant must have asked for a licence from the patent holder under reasonable terms and been unable to obtain one. - Public interest / national emergency / anti-competitive practice / government use The law allows the government (or Tribunal) to issue compulsory licences for patents covering inventions (products or processes) which are declared to be of “vital importance” to public interest, public health, economy, etc. More information can be found [here](https://www.wipo.int/wipolex/en/legislation/details/23216 ). ### Indonesia issued on March 01, 2007 [[Indonesia]]'s provisions on compulsory licences can be in the Patent Law No. 13 of 2016. Under the Indonesian Patent Law, compulsory licenses can be granted under the following circumstances: - Non-Working of the Patent: If a patented invention is not exploited within 36 months from the date of grant, any party may request a compulsory license. The law aims to prevent patents from remaining dormant and to encourage their utilization for commercial and public health purposes. - Public Interest Considerations: A compulsory license may be granted if the patent holder or licensee implements the patent in a manner that contravenes public interest, such as actions leading to monopolistic practices or unfair competition. - National Emergencies or Public Health Crises: The Indonesian government can grant compulsory licenses to address public health emergencies, including the importation of patented drugs not locally produced and the exportation of locally produced patented drugs to other countries facing health crises. More information can be found [here](https://www.wipo.int/wipolex/en/legislation/details/16392?). ## Other products issued by the same manufacturer [[EFV]] [[Finasteride]] [[Etoricoxib]] [[Imipenem/Cilastatin]] ## Other products for the same disease [[ARVs]] [[All medicines]] [[Dolutegravir]] [[3TC/D4T/NVP]] [[NFV]] [[EFV/FTC/TDF, 3TC/AZT/EFV]] [[RTV]] [[NVP, 3TC, 3TC/AZT]] [[ARVs +]] [[AZT]] [[T-20]] [[DDI, IDV, LPV/r]] [[3TC/AZT/NVP]] [[LPV/r]] [[IDV, LPV/r, NVP, TDF]] [[AZT, 3TC, D4T, NVP, 3TC/AZT]] [[NVP, AZT]] [[3TC/AZT]] [[3TC, D4T, AZT, NVP, EFV, TDF, DDI, LPV/r, SQV, RTV, NFV, ABC]] [[ATV]] [[NVP]] [[ABC/3TC]] [[3TC]] [[3TC, NVP, AZT]] [[NVP, 3TC]] [[3TC, 3TC/AZT, 3TC/AZT/NVP, 3TC/D4T, 3TC/D4T/NVP, DDI, EFV, IDV]] [[AZT, 3TC, AZT/3TC, NVP]] [[RAL]] [[EFV, NVP, 3TC/AZT]] [[3TC/D4T/NVP, LPV/r]] [[TDF/3TC]] [[AZT, 3TC+AZT]]